Alliances
The collaboration will establish a study protocol with an initial focus on breast cancer to provide the regulatory agency with information on the evolving treatment landscape, including insight on treatment variation within defined subpopulations of patients with the disease.
The first project the companies aim to develop is a companion diagnostic for Vitrakvi, the only TRK inhibitor approved in the U.S. for patients with TRK fusion cancer across all solid tumors.
The deal broadens their work together from three to six programs for rare genetic diseases, as well as rights to collaborative R&D of novel gene therapies for lysosomal disorders and 12 additional rare diseases.
Eli Lilly announced it has inked a license agreement with Centrexion Therapeutics to acquire the exclusive global rights to CNTX-0290.
In addition to education and training, it will offer Bayer’s complete portfolio of recombinant Factor VIII treatments to healthcare providers in more than 60 countries.
Medigene AG announced that it entered into a Clinical Trial Agreement with the Leiden University Medical Center, the Netherlands, to conduct a Phase I clinical trial with Medigene’s T cell receptor modified T cell therapy MDG1021 targeting the HA-1 antigen.
Biopharma companies from across Europe share pipeline and strategy updates.
Synlogic is partnering with Roche to develop Synlogic’s SYNB1891 with Roche’s checkpoint inhibitor Tecentriq (atezolizumab) in advanced solid tumors.
Verily announced a strategic collaboration deal with Novartis, Otsuka, Pfizer, Sanofi and six major health systems.
The collaboration will focus on Inovio’s VGX-3100, which stimulates a specific immune response to HPV-16 and HPV-18, targeting the infection and causing destruction of precancerous cells.
PRESS RELEASES